LONDON – Seventeen years of research into the intricacies of the transcription factor NF-κB (nuclear factor kappa-light-chain enhancer of activated B-cells) has culminated in the formation of Kesios Ltd., which has £5.75 million (US$9.2 million) initial funding to deliver human data validating a highly specific cancer target on the NF-κB pathway.